Eculizumab

From Wikipedia, the free encyclopedia

You have new messages (last change).

Eculizumab is a monoclonal antibody directed against the complement protein C5. This antibody blocks the cleavage of C5 and halts the process of complement-mediated cell destruction. Eculizumab has been shown to be effective in treating paroxysmal nocturnal hemoglobinuria.[1]

[edit] Reference

  1. ^ Hillmen P, Young N, Schubert J, Brodsky R, Socié G, Muus P, Röth A, Szer J, Elebute M, Nakamura R, Browne P, Risitano A, Hill A, Schrezenmeier H, Fu C, Maciejewski J, Rollins S, Mojcik C, Rother R, Luzzatto L (2006). "The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria.". N Engl J Med 355 (12): 1233-43. PMID 16990386.
Retrieved from "http://en.wikipedia.org../../../e/c/u/Eculizumab.html"